Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord 1999;29:191-4. View abstract.

Reap EA, Lawson JW. Stimulation of the immune response by dimethylglycine, a nontoxic metabolite. J Lab Clin Med 1990;115:481-6. View abstract.

Weiss RC. Immunologic responses in healthy random-source cats fed N,N-dimethylglycine-supplemented diets. Am J Vet Res 1992;53:829-33. View abstract.

Gascon G, Patterson B, Yearwood K, Slotnick H. N,N-dimethylglycine and epilepsy. Epilepsia 1989;30:90-3. View abstract.

Freed WJ. Prevention of strychnine-induced seizures and death by the N-methylated glycine derivatives betaine, dimethylglycine and sarcosine. Pharmacol Biochem Behav 1985;22:641-3. View abstract.

Graber CD, Goust JM, Glassman AD, et al. Immunomodulating properties of dimethylglycine in humans. J Infect Dis 1981;143:101-5. View abstract.

Roach ES, Carlin L. N,N dimethylglycine for epilepsy [letter]. N Engl J Med 1982;307:1081-2.

Freed WJ. N,N-dimethylglycine, betaine and seizures [letter]. Arch Neurol 1984;41:1129-30. View abstract.

Ward TN, Smith EB, Reeves AG. Dimethylglycine and reduction of mortality in penicillin-induced seizures [letter]. Ann Neurol 1985;17:213.

Hoorn AJ. Dimethylglycine and chemically related amines tested for mutagenicity under potential nitrosation conditions. Mutat Res 1989;222:343-50. View abstract.

Wolfsegger T, Böck K, Schimetta W, von Oertzen TJ, Assar H. N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial. Neurol Res Pract 2021;3(1):29. View abstract.